Upcoming Webinars
Thursday September 12

Otitis Externa: Treatment Frustrations and Potential Solutions

09/12/2024 

Read MoreRead Less

Register Here

Date: Thursday, September 12

Time: 7PM ET/6PM CT/5PM MT/4PM PT

In this session, basic principles to improving treatment outcomes with canine otitis externa (OE) will be covered. Time will be spent discussing the importance of glucocorticoids, identifying the primary causes for disease and drug selection in the management of canine OE. Additionally, approaches for avoiding common pitfalls will be covered along with strategies to bolster client compliance.

This is a live event only and will not be recorded. 

This program has been approved for 1.0 hour of continuing education credit in jurisdictions which recognize RACE approval. Virbac is approved as a NY State sponsor of continuing education for veterinarians and veterinary technicians. You must attend the full presentation to receive CE credit.

Chelsea Villarino

Technical Service Veterinarian

Dr. Chelsea Villarino is a 2015 DVM graduate of North Carolina State University. After graduation, Dr. V completed a small animal rotating internship at Veterinary Specialty Hospital in San Diego, California. She practiced companion animal general and ER medicine for 5 years before joining Virbac.

 

Monday September 23

STELFONTA (tigilanol tiglate injection): Practical aspects, Case reports and Tips from veterinarians who are using it

09/23/2024 

Read MoreRead Less

Corporate and Commercial Photographer for Worldwide Assignments

Register Here

Date: Wednesday, September 18

Time: 8PM ET/7PM CT/6PM MT/5PM PT

Many of you have already experienced STELFONTAⓇ(tigilanol tiglate injection) on your own, while some of you remain curious to try STELFONTA. In this webinar, several of your colleagues will share their individual cases and experience with STELFONTA.

Please join us to learn more about this exciting option for mast cell tumor treatment in dogs!

This is a live event only and will not be recorded.

This program has been approved for 1.0 hour of continuing education credit in jurisdictions which recognize RACE approval. Virbac is approved as a NY State sponsor of continuing education for veterinarians and veterinary technicians. You must attend the full presentation to receive CE credit.

STELFONTA is an FDA approved, intratumoral injection indicated for use in dogs for the local treatment of: Non-metastatic cutaneous mast cell tumors anywhere on the body, Non-metastatic subcutaneous mast cell tumors located at or distal to, the elbow or hock

Jay Tischendorf

Field Technical Services Veterinarian @ Virbac

Virbac vet J Tischendorf has worked coast to coast in animal & human pharma + private & relief practice. His interests range from analgesia to zoonoses. J is Fear Free & Human-Animal Bond certified, and an Expert Animal Cruelty Investigator. J often speaks at vet, ecology, and human med symposia.

 

IMPORTANT SAFETY INFORMATION

Accidental self-injection of STELFONTA® (tigilanol tiglate injection) may cause severe wound formation. To decrease the risk of accidental self-injection, sedation of the dog may be necessary. In dogs, do not inject STELFONTA into subcutaneous mast cell tumors located above the elbow or hock. Formation of wounds, possibly extensive, is an intended and likely response to treatment with STELFONTA along with associated swelling, bruising and pain; these wounds are expected to heal. Some of these cases resulted in amputation. Appropriate pre- and post-treatment medications must be given, including a corticosteroid plus blocking agents for both H1 and H2 receptors, in order to decrease the potential for severe systemic adverse reactions, including death, from mast cell degranulation. For full prescribing information, contact VIRBAC at 1-800-338-3659 or visit https://vet-us.virbac.com/stelfonta.

Tuesday October 01

Unleashing the Secrets of Canine Osteoarthritis: From Creaky Joints to Tail-Wagging Solutions!

10/01/2024 

Read MoreRead Less

Register Here

Date: Tuesday, October 1st

Time: 7PM ET/6PM CT/5PM MT/4PM PT

Ever wonder how exactly osteoarthritis (OA) medications and supplements help your canine patients? Could one shot be all that's needed? Why do joint supplements have antioxidants in them? In this presentation, we will review the canine diarthrodial joint anatomy with particular focus on the extracellular matrix of hyaline cartilage. We will discuss the pathophysiology of inflammation and pain involved with canine OA. From this new knowledge, we can discuss common OA medications/supplements and how their efficacy impacts the OA degenerative process. By the end of the presentation, attendees will have a keen understanding of how many joint supplement ingredients work (or don't work) according to recent research. Finally, we will conclude with the revelation of a secret yet simple solution for helping your canine OA patients. Sign up today to learn this and much more!

This is a live event only and will not be recorded.

This program has been approved for 1.0 hour of continuing education credit in jurisdictions that recognize RACE approval. Virbac is NYSED approved as a New York State sponsor of continuing education for veterinarians and veterinary technicians.

*You must attend the full presentation to receive CE Credit.

Mark Hope

Senior Technical Service Veterinarian @ Virbac

Dr. Mark Hope is a Senior Technical Services Veterinarian for Virbac. He spent 16 years in private practice before joining Virbac in 2017. Dr. Hope currently provides technical support and education of Virbac products in the Southeastern United States.

Wednesday October 09

STELFONTA (tigilanol tiglate injection): Practical aspects, Case reports and Tips from veterinarians who are using it

10/09/2024 

Read MoreRead Less

Register Here

Date: Wednesday, October 9

Time: 7PM ET/6PM CT/5PM MT/4PM PT

Many of you have already experienced STELFONTAⓇ(tigilanol tiglate injection) on your own, while some of you remain curious to try STELFONTA. In this webinar, several of your colleagues will share their individual cases and experience with STELFONTA.

Please join us to learn more about this exciting option for mast cell tumor treatment in dogs!

This is a live event only and will not be recorded.

This program has been approved for 1.0 hour of continuing education credit in jurisdictions which recognize RACE approval. Virbac is approved as a NY State sponsor of continuing education for veterinarians and veterinary technicians. You must attend the full presentation to receive CE credit.

STELFONTA is an FDA approved, intratumoral injection indicated for use in dogs for the local treatment of: Non-metastatic cutaneous mast cell tumors anywhere on the body, Non-metastatic subcutaneous mast cell tumors located at or distal to, the elbow or hock

Chelsea Villarino

Technical Service Veterinarian

Dr. Chelsea Villarino is a 2015 DVM graduate of North Carolina State University. After graduation, Dr. V completed a small animal rotating internship at Veterinary Specialty Hospital in San Diego, California. She practiced companion animal general and ER medicine for 5 years before joining Virbac.

 

IMPORTANT SAFETY INFORMATION

Accidental self-injection of STELFONTA® (tigilanol tiglate injection) may cause severe wound formation. To decrease the risk of accidental self-injection, sedation of the dog may be necessary. In dogs, do not inject STELFONTA into subcutaneous mast cell tumors located above the elbow or hock. Formation of wounds, possibly extensive, is an intended and likely response to treatment with STELFONTA along with associated swelling, bruising and pain; these wounds are expected to heal. Some of these cases resulted in amputation. Appropriate pre- and post-treatment medications must be given, including a corticosteroid plus blocking agents for both H1 and H2 receptors, in order to decrease the potential for severe systemic adverse reactions, including death, from mast cell degranulation. For full prescribing information, contact VIRBAC at 1-800-338-3659 or visit https://vet-us.virbac.com/stelfonta.

Wednesday October 09

Otitis Externa: Treatment Frustrations and Potential Solutions

10/09/2024 

Read MoreRead Less

Corporate and Commercial Photographer for Worldwide Assignments

Register Here

Date: Wednesday, October 9

Time: 8PM ET/7PM CT/6PM MT/5PM PT

In this session, basic principles to improving treatment outcomes with canine otitis externa (OE) will be covered. Time will be spent discussing the importance of glucocorticoids, identifying the primary causes for disease and drug selection in the management of canine OE. Additionally, approaches for avoiding common pitfalls will be covered along with strategies to bolster client compliance.

This is a live event only and will not be recorded. 

This program has been approved for 1.0 hour of continuing education credit in jurisdictions which recognize RACE approval. Virbac is approved as a NY State sponsor of continuing education for veterinarians and veterinary technicians. You must attend the full presentation to receive CE credit.

Jay Tischendorf

Field Technical Services Veterinarian @ Virbac

Virbac vet J Tischendorf has worked coast to coast in animal & human pharma + private & relief practice. His interests range from analgesia to zoonoses. J is Fear Free & Human-Animal Bond certified, and an Expert Animal Cruelty Investigator. J often speaks at vet, ecology, and human med symposia.

 

IMPORTANT SAFETY INFORMATION

Accidental self-injection of STELFONTA® (tigilanol tiglate injection) may cause severe wound formation. To decrease the risk of accidental self-injection, sedation of the dog may be necessary. In dogs, do not inject STELFONTA into subcutaneous mast cell tumors located above the elbow or hock. Formation of wounds, possibly extensive, is an intended and likely response to treatment with STELFONTA along with associated swelling, bruising and pain; these wounds are expected to heal. Some of these cases resulted in amputation. Appropriate pre- and post-treatment medications must be given, including a corticosteroid plus blocking agents for both H1 and H2 receptors, in order to decrease the potential for severe systemic adverse reactions, including death, from mast cell degranulation. For full prescribing information, contact VIRBAC at 1-800-338-3659 or visit https://vet-us.virbac.com/stelfonta.

 

Important Safety Information  

EASOTIC® (hydrocortisone aceponate, miconazole nitrate, gentamicin sulfate) Otic Suspension for Dogs: For otic (ear) use in dogs only. Humans with known or suspected hypersensitivity to hydrocortisone, aminoglycoside antibiotics, or azole antifungals should not handle this product. Contraindicated in dogs with known or suspected hypersensitivity to corticosteroids, imidazole antifungals, or aminoglycoside antibiotics. Do not use in dogs with known tympanic membrane (ear drum) perforation. The safe use of EASOTIC Otic Suspension in dogs used for breeding purposes has not been evaluated. Do not administer orally. For full prescribing information, contact Virbac at 1-800-338-3659 or view the Product Insert